菜单
Pretreat with a potent bisphosphonate before surgery for pagetic bone neoplasm to reduce bleeding from adjacent pagetic bone. Triggers include suspicion of osteosarcoma or giant cell tumor in pagetic bone prompting orthopedic surgical referral.
默认使用会先检查来源的 Prompt；你也可以切换为直接命令，或下载本地副本。
决定是否安装前，请先阅读 SKILL.md，以及 SkillsMP 当前展示的配套文件。
用 Codex 或 Claude 帮你安装 复制这段 Prompt，粘贴到 Codex、Claude 或其他助手里，让它检查 Skill 页面并帮你完成安装。
直接命令不会经过审查 Prompt；运行前请先检查来源。
npx skills add https://github.com/dromlakhani/MD2SKILL --skill endo-paget-bisphosphonate-neoplasm-pretreatment命令会保持在同一行。复制前请横向滚动并检查完整内容。
想先保存到本地？可下载 SkillsMP 当前能够提供的文件。
基于 SOC 职业分类
正在显示 SKILL.md
| name | endo-paget-bisphosphonate-neoplasm-pretreatment |
| description | Pretreat with a potent bisphosphonate before surgery for pagetic bone neoplasm to reduce bleeding from adjacent pagetic bone. Triggers include suspicion of osteosarcoma or giant cell tumor in pagetic bone prompting orthopedic surgical referral. |
Confirm Paget’s disease diagnosis (plain radiographs, bone scan), assess for neoplastic lesion (MRI/CT, biopsy if indicated), obtain orthopedic oncology evaluation, check serum ALP, bone turnover markers, renal function, calcium, vitamin D, and coagulation status. Document findings and proceed to risk assessment.
Is there suspicion of osteosarcoma or giant cell tumor arising in pagetic bone? If yes, proceed to surgical planning; if no, manage Paget’s disease per standard care and do not pursue neoplasm‑specific pretreatment.
If the orthopedic surgeon plans operative intervention (biopsy, resection, or stabilization), classify as needing preoperative bisphosphonate pretreatment; if surgery is not planned, no pretreatment is required for bleeding risk reduction.
Administer a potent bisphosphonate (e.g., intravenous zoledronate 5 mg) 1–2 months preoperatively after correcting vitamin D deficiency and ensuring euglycemia and adequate renal function; if bisphosphonate is contraindicated, consider delaying surgery or using alternative hemostatic measures.
Do not give bisphosphonate in severe renal impairment (eGFR <35 mL/min), untreated hypocalcemia, or vitamin D deficiency; avoid high‑dose etidronate preoperatively due to fracture risk; do not delay definitive oncologic surgery unnecessarily; monitor for acute phase reaction, hypocalcemia, and atypical femoral fracture with long‑term use.
A 68‑year‑old with known Paget’s disease of the femur presents with worsening pain; MRI shows a lytic lesion suggestive of osteosarcoma. Orthopedic oncology confirms suspicion and plans wide resection. Pretreatment with IV zoledronate 5 mg is given 6 weeks pre‑operatively after vitamin D supplementation and confirmation of normal renal function. Surgery proceeds with markedly reduced intraoperative bleeding and no transfusion requirement.
Source: Paget’s Disease of Bone: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI: 10.1210/jc.2014-2910